Rocket Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent ProgressBusiness Wire • 05/10/21
Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell TherapyBusiness Wire • 04/27/21
Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual MeetingBusiness Wire • 04/14/21
Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-IBusiness Wire • 03/29/21
Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase DeficiencyBusiness Wire • 03/22/21
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-IBusiness Wire • 03/09/21
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational ResultsBusiness Wire • 02/25/21
Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy PipelineBusiness Wire • 01/11/21
Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/21
Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesBusiness Wire • 12/14/20
Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon DiseaseBusiness Wire • 12/08/20
Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 12/07/20
Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 12/06/20
Rocket Pharmaceuticals to Hold Webcast for Investors Highlighting Data Presented at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 12/02/20
Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant OsteopetrosisBusiness Wire • 11/13/20
Rocket Pharmaceuticals to Present Data from its Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Pyruvate Kinase Deficiency Programs at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 11/04/20
Rocket Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent ProgressBusiness Wire • 11/04/20
Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the European Society for Immunodeficiencies 2020 MeetingBusiness Wire • 10/16/20